• Benzinga’s Bulls And Bears Of The Week: Microsoft, Netflix, Twitter And More

    Benzinga's Bulls And Bears Of The Week: Microsoft, Netflix, Twitter And More* Benzinga has examined the prospects for many investor favorite stocks over the past week. * This week's bullish calls included the e-commerce and electric vehicle leaders. * Streaming and semiconductor giants were among the week's bearish calls.Those investors who declined to sell in May and go away are keeping a close eye on how state "reopenings" are affecting stocks, sectors and the economy, and they also are bracing for the kickoff of a new earnings reporting season. The Oracle of Omaha made a notable acquisition this past week as well.The big three U.S. indexes ended the week with gains of at least 1%. The clear winner was the Nasdaq, which rose by about 4%.As usual, Benzinga continues to examine the prospects for many of the stocks most popular with investors. Here are some of this past week's most bullish and bearish posts that are worth another look.Bulls "Amazon Shares Pass ,000 And The Stock Has More Room To Run" by Priya Nigam suggests that prospects for Amazon.com, Inc (NASDAQ: AMZN) still may not be completely priced in, despite this year's run.Short squeezes could drive significant additional upside at Tesla Inc (NASDAQ: TSLA), according to Wayne Duggan's "Analyst: Tesla And Nikola Are The 'Silent Short Seller Killers'."Shanthi Rexaline's "Microsoft Gets New Street-High Price Target, Analyst Sees Transformational Cloud Story In Redmond" reveals why Microsoft Corporation (NYSE: MSFT) is a huge beneficiary of recent secular trends.In "Square Analyst Sees Market Share Opportunity With Direct Deposit," Robert Schultz examines why its direct deposit feature could provide a sizable boost for Square Inc (NYSE: SQ) shares.For additional bullish calls, also have a look at US Companies In 'Much Better Shape' Than Wall Street Thinks: Here's Why and 4 Underappreciated New Money Ideas For The Second Half Of 2020.Bears The outperformance of Netflix Inc (NASDAQ: NFLX) shares makes its valuation less attractive. So says "4 Reasons Why Netflix's Stock Has Outperformed The Market" by Shanthi Rexaline.In Priya Nigam's "6 Reasons Why Goldman Sachs Is Bearish On Intel," see why weakening PC demand and weak enterprise spending are just two of the headwinds that Intel Corporation (NASDAQ: INTC) faces.Jayson Derrick's "Why A Twitter Subscription Service Won't 'Move The Needle'" looks at why one analyst is not impressed with the prospects for the new Twitter Inc (NYSE: TWTR) service."2 Stocks To Short In Q3, According To Bank Of America" by Wayne Duggan discusses why things are not likely to get any better for ON Semiconductor Corp (NASDAQ: ON) for the rest of the year. Plus, one other short candidate.Be sure to check out 13 Reasons COVID-19 Could Weigh On The Stock Market 'For Several Years' and 2009 Playbook Suggests Stock Market Is 'Too High' for additional bearish calls.Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.See more from Benzinga * Barron's Picks And Pans: Chevron, Goldman Sachs, Progressive And More * Benzinga's Bulls And Bears Of The Week: Amazon, Netflix, Starbucks And More * Barron's Picks And Pans: Sysco, Twitter, Zoom Video And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2Wc2zmK

  • Work remotely from Barbados for a year

    Work remotely from Barbados for a yearBarbados has a proposition for those working from home that is hard to pass up.

    from Yahoo Finance https://ift.tt/2WaOfuA

  • Did Hedge Funds Make The Right Call On Immunomedics, Inc. (IMMU) ?

    Did Hedge Funds Make The Right Call On Immunomedics, Inc. (IMMU) ?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

    from Yahoo Finance https://ift.tt/2W6EOwf

  • Infectious Diseases Specialist on the ‘snowball effect’ that occurs when labs are overwhelmed with COVID-19 tests

    Infectious Diseases Specialist on the 'snowball effect' that occurs when labs are overwhelmed with COVID-19 testsDr. Isaac Bogoch, Infectious Diseases Specialist, joined Yahoo Finance’s The Final Round to discuss the latest developments regarding the coronavirus as cases in the U.S. surpass 3.1 million.

    from Yahoo Finance https://ift.tt/38I79y2

  • Dow jumps as Gilead says drug reduces COVID-19 death risk

    Dow jumps as Gilead says drug reduces COVID-19 death riskDr. Alison Haddock,Emergency Medicine Physician and Assistant Professor of Emergency Medicine at Baylor University, joins Yahoo Finance’s Zack Guzman to break down the latest coronavirus developments as U.S. cases surpass 3 million.

    from Yahoo Finance https://ift.tt/2ZXRIxx

  • Beyond Meat sinks after Citigroup’s ‘sell’ rating

    Beyond Meat sinks after Citigroup's ‘sell’ ratingYahoo Finance’s talent Emily McCormick Kristin Myers to discuss why Citi’s analyst initiated coverage of Beyond Meat with a sell rating, citing concerns about rising competition.

    from Yahoo Finance https://ift.tt/2Wat77C

  • What You Need To Know About Editas Medicine, Inc.’s (NASDAQ:EDIT) Investor Composition

    What You Need To Know About Editas Medicine, Inc.'s (NASDAQ:EDIT) Investor CompositionA look at the shareholders of Editas Medicine, Inc. (NASDAQ:EDIT) can tell us which group is most powerful. Generally…

    from Yahoo Finance https://ift.tt/32e51wD

  • How Much Will The Tesla Stock Bubble Inflate?

    How Much Will The Tesla Stock Bubble Inflate?Tesla (TSLA) stock soared past $1,400 a share today, and talk about whether it’s in a bubble has been reignited. Several analysts have weighed in on the EV maker today, and even some bears are starting to say that the shares could keep rising. However, one author suggests that Tesla stock is indeed in a bubble […]

    from Yahoo Finance https://ift.tt/2OdX5Dw

  • Mesoblast expands compassionate use COVID-19 program

    Mesoblast expands compassionate use COVID-19 programMesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance’s On the Move to discuss what this development could mean in the fight against the virus.

    from Yahoo Finance https://ift.tt/2Ofx2f0

  • Oppenheimer: 3 “Strong Buy” Stocks With Over 30% Upside Ahead

    Oppenheimer: 3 “Strong Buy” Stocks With Over 30% Upside AheadAre the violent stock market movements here to stay? Investors see plenty of cause for worry, in rising coronavirus case rates that many say portend a second wave of the pandemic. In addition, some states are extending lockdown policies. That said, watching the markets for the past few months, Oppenheimer’s asset management chief strategist John Stoltzfus sees reasons for a bullish outlook. He believes that volatility will rule through 2H20, but that markets will start rising again at the end of the year. Stoltzfus says that when the bull comes to run, investors will jump on, arguing they are “waiting for some catalyst to cross the tape that will justify taking near-term profits without FOMO…” Among the catalysts that Stoltzfus sees as likely is the November election. Whatever the outcome, he believes that the resolution of uncertainty once the results are in will put investors in a buying mood. Stoltzfus has recommendations for that, too: “We like consumer discretionary. We also like industrials, because industrial stocks today use a lot more technology than ever before…” Stoltzfus isn’t alone at his firm in pointing out reasons for a bullish market stance. Oppenheimer’s stock analysts have been busy putting the strategist’s tips into concrete recommendations. Using the TipRanks database, we’ve pulled up the details on three of those calls. Each offers investors plenty of upside, starting at 30%; let’s find out what else makes them so compelling. Ulta Beauty, Inc. (ULTA) Stoltzfus is bullish on the consumer discretionary segment, and so, first on our list is a cosmetic company. Ulta is a chain of beauty care stores. The company boasts an $11 billion market cap – a testament to the strength of the beauty sector – and nearly 1,200 locations spread across all 50 states. As part of its response to the COVID-19 pandemic, the company offered a curbside pickup service at over 700 locations. Even so, the Q1 ‘corona quarter’ was tough on Ulta. The company lost $1.12 per share, and the stock price is still down 35% from its February peak. Lower sales during the period of shutdown policies and lower margins during the quarter were the main drivers of the poor performance. This is borne out by comp sales, which fell 35% during Q1 compared to a gain of 7% in the prior-year quarter. As a liquidity measure, Ulta drew some $800 million from its $1 billion credit facility during the corona crisis. The funds were used for general operation. In a positive note, the company has been reopening stores since mid-May, and is forecasting a positive – albeit modest – net profit for Q2. Oppenheimer’s Rupesh Parikh sees the current environment as a buying opportunity for investors. He writes, “With the resurgence of coronavirus infections and likely conservative planning from the ULTA management team, we are assuming a slower 2H20 recovery. Consistent with our recent views, we believe investors should take advantage of weakness in accumulating shares and not chase strength. We believe ULTA should emerge with stronger share gains driven by omni-channel investments and department store challenges post-crisis.” To this end, Parikh backs his Buy recommendation with a $270 price target, suggesting a 38% upside potential for the stock in the coming year. (To watch Parikh’s track record, click here) Overall, ULTA gets a Strong Buy rating from the analyst consensus, based on 12 Buys and 4 Holds given in recent weeks. The general thought is that this company is fundamentally sound despite the pandemic. Shares are selling for $195.99, and the average price target of $264.93 implies a one-year upside potential of 35%. (See Ulta stock analysis on TipRanks) WillScot Mobile Mini Holdings (WSC) Next up, WillScot is a holding company with subsidiaries involved in the modular office space sector. This unusual niche is probably more familiar to you than you realize; modular offices are commonly seen at construction sites, where modified containers are used as on-site office space. WillScot produces the luxury version. The company saw a unique opportunity arise during the coronavirus pandemic, as a sudden need arose for temporary testing sites, quarantine units, and the like. It was able to use that need to its advantage. Besting the consensus estimate, WSC reported a 9-cent per share profit. Along with the better-than-expected quarter, WillScot also completed an offer of $650 million in senior secured notes, a move that improves liquidity and gives the company flexibility in dealing with the ongoing public health crisis. The note offering also allowed WillScot to complete a merger with Mobile Mini during the second quarter. The deal created a combined company worth $6.6 billion, with a leading market share in the North American modular sector. Scott Schneeberger, a 4-star analyst with Oppenheimer, points out that WillScot’s business model lends itself to recurring revenue over the long-term, keeping the company resilient. He writes, “Its rental assets typically remain on-site through project-end even if the project were suspended a few months. WSC indicated in early-May no material COVID-19 impact to the lease duration/renewal/payment activity of its existing uniton-rent installed base.” In line with his positive view of the company’s business, Schneeberger rates WSC a Buy, and increases the price target to $17. This new target implies an upside potential of 38% for the coming 12 months. (To watch Schneeberger’s track record, click here) Wall Street is slightly more bullish than Schneeberger. The Strong Buy analyst consensus rating is unanimous, based on 5 Buy ratings, and the average price target comes in at $18. This suggests a one-year upside potential of 46% for the stock. (See WillScot stock analysis on TipRanks) DraftKings, Inc. (DKNG) Last on our list is DraftKings, the online venue for sports fantasy leagues. In a way, DraftKings has come into its own during the coronavirus crisis. Major sports have been mostly halted for now – but when they start up, they will do so without fans. This has already happened in German soccer. That will leave fantasy leagues, which are already popular, as the main outlet for fan participation. At least that’s the thought process behind the company’s stock surge which began in May. Despite a net loss of $74 million in Q1, DKNG shares are up 80% since February 19, dramatically outperforming the broader markets. In its earnings report, the company stated that it does not expect a long-term income hit from the pandemic, and has not changed its plans for 2H20. As its business is conducted entirely online, direct customer contact is not a problem. Additionally, with both the NBA and Major League Baseball planning truncated regular season play for the second half of the year, DraftKings has reason to believe that the fantasy leagues will return to play. 5-star analyst Jed Kelly initiated coverage of DKNG for Oppenheimer with a Buy rating. He specifically cited a new niche as an opportunity for the company: legalized in-game sports betting. Kelly says, “Legalized sports betting and iGaming markets are in their very early stages of growth, and we see an $18 billion revenue opportunity at scale, that also benefits from a sophisticated in-game wagering market.” Noting that DraftKings already operates online and in-game, he sees the company as having a uniquely strong position here. Kelly backs his Buy rating with a $46 price target, suggesting a robust 42% upside potential for the stock. (To watch Kelly’s track record, click here) DKNG is trading at $32.43 now, and the average price target of $48 implies a 48% upside potential. The analyst consensus here is a Strong Buy, based on 11 reviews breaking down as 10 Buys and 1 Hold. (See DraftKings stock analysis on TipRanks)

    from Yahoo Finance https://ift.tt/3eqbRl8